Portrait of Laura L. Koth
ucsf logo

Laura L. Koth, MD

Chronic Obstructive Pulmonary Disease • Interstitial Lung DiseaseCo-director, UCSF Interstitial Lung Disease Center of Excellence
Interstitial Lung Disease (ILD) Parnassus
415-353-2577
Portrait of Laura L. Koth
Portrait of Laura L. Koth
ucsf logo

Laura L. Koth, MD

Chronic Obstructive Pulmonary Disease • Interstitial Lung DiseaseCo-director, UCSF Interstitial Lung Disease Center of Excellence
Interstitial Lung Disease (ILD) Parnassus
415-353-2577

On this page

About me

Dr. Laura Koth is a pulmonologist and an expert in interstitial lung disease. She is co-director of UCSF's interstitial lung disease center of excellence.

Koth's research activities focus on the mechanisms of lung inflammation and macrophage activation. Macrophages are a type of white blood cell with important roles in immune response.

Koth earned her medical degree from Harvard Medical School. She completed residency training in internal medicine at Massachusetts General Hospital, followed by a fellowship in pulmonary and critical care medicine UCSF. She joined the UCSF faculty in 2003.

Education & training

Board certification

  • Pulmonary Disease, American Board of Internal Med/Pulmonary Disease

Fellowship

  • UCSF Medical Center - OMAG

Residency

  • Massachusetts General Hospital

Internship

  • Massachusetts General Hospital

Degree

  • MD, Harvard Medical School

My expertise

Locations

    My work

    Inside the Interstitial Lung Disease (ILD) Program

    Learn how Dr. Koth and her team leverage research, collaboration and the latest medications to support patients with ILD.

    My research

    Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.

    For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.